Allergic Conjunctivitis

Clinical Snapshot

Allergic conjunctivitis is a bilateral conjunctival reaction to an environmental or contact allergen, and one of the most common causes of a red, irritated eye.^[1] Itching is the dominant symptom — if a patient with a red eye does not report itching, seriously reconsider allergic conjunctivitis as the cause. The essential first task is not treating the itch — it is confirming this is conjunctivitis and not a sight-threatening red-eye mimic (angle-closure glaucoma, iritis/uveitis, scleritis, keratitis), and recognizing when allergic eye disease is severe enough (vernal or atopic keratoconjunctivitis) to threaten the cornea and need specialist-directed therapy.^[2]

Recognize the Condition

Typical (seasonal/perennial) allergic conjunctivitis

Bilateral, itch-predominant, watery/stringy mucoid discharge, chemosis (conjunctival swelling), and lid edema. Often seasonal (pollen) or perennial (dust mite, pet dander), or triggered by a known contact allergen or contact lens wear (giant papillary conjunctivitis). Usually a history of atopy, other allergies, or asthma/eczema.

Severe allergic eye disease (vernal and atopic keratoconjunctivitis)

Vernal keratoconjunctivitis

A severe, chronic allergic eye disease predominantly affecting children and young adults (more common in males, warmer climates), with giant papillae on the upper tarsal conjunctiva, thick ropy mucoid discharge, and a real risk of corneal involvement (shield ulcer) if inadequately treated.

Atopic keratoconjunctivitis

A severe, chronic allergic eye disease in adults with atopic dermatitis, again with real potential for corneal scarring and vision loss if undertreated — both vernal and atopic keratoconjunctivitis are a different severity tier from typical seasonal allergic conjunctivitis and need specialist involvement.

Risk Factors

History of atopy — asthma, eczema, allergic rhinitis, or other known allergies.
Seasonal pollen exposure, or perennial exposure to dust mite/pet dander/mould.
Contact lens wear (giant papillary conjunctivitis) or known contact allergen exposure (cosmetics, preservatives in eye drops).
Personal history of atopic dermatitis (risk factor for atopic keratoconjunctivitis specifically).
Male sex, younger age, and warmer climate (risk factors for vernal keratoconjunctivitis specifically).

Red Flags & Refer

Refer immediately to an ophthalmologist (or an optometrist if one is not available) for any of the following:

Marked redness concentrated at the corneoscleral junction (limbal/ciliary injection), especially if one-sided.
White corneal opacity or haze.
Moderate-to-severe pain or photophobia not relieved by a test dose of topical anesthetic.
Reduced visual acuity.
A contact-lens wearer with suspected corneal infiltrate/ulcer.
Suspected vernal or atopic keratoconjunctivitis (giant papillae, thick ropy discharge, photophobia, or any corneal involvement) — these need specialist-directed therapy, not standard over-the-counter allergy eye drops, given the real risk of permanent corneal scarring.^[3]

Assessment & Diagnosis

Differentiating bacterial, viral, and allergic conjunctivitis, and blepharitis

These four conditions are the most commonly confused causes of a red, irritated eye in community practice. Distinguishing them correctly determines whether the patient needs an antibiotic, supportive care, an antihistamine, or eyelid hygiene — and getting it wrong means either an unnecessary antibiotic or a missed diagnosis.

Bacterial conjunctivitis with diffuse conjunctival redness and purulent yellow discharge

Bacterial conjunctivitis — purulent discharge with morning crusting. (CNX OpenStax, CC BY 4.0, Wikimedia Commons)

Viral conjunctivitis with marked diffuse redness and watery discharge

Viral conjunctivitis — marked redness, watery discharge, often with a preauricular node. (Joyhill09, CC BY-SA 3.0, Wikimedia Commons)

Allergic conjunctivitis with conjunctival redness, chemosis, and eyelid swelling

Allergic conjunctivitis — itching is the dominant symptom, often with chemosis (conjunctival swelling). (James Heilman, MD, CC BY-SA 4.0, Wikimedia Commons)

Anterior blepharitis with crusting and scale at the base of the eyelashes

Blepharitis — crusting and scale at the lash base; this is an eyelid problem, not a conjunctival infection, though it can cause secondary conjunctivitis. (Imrankabirhossain, CC BY-SA 4.0, Wikimedia Commons)

Feature	Bacterial conjunctivitis	Viral conjunctivitis	Allergic conjunctivitis	Blepharitis
Laterality	Often one eye first, may spread to the other	Usually starts in one eye, spreads to the other within days	Bilateral, essentially always	Bilateral, essentially always
Discharge	Purulent, thick, yellow-green; lids stuck together on waking	Watery to mucoid; no true pus	Watery, stringy/mucoid	Greasy debris and crusting at the lash base, not a true discharge
Itching	Minimal or absent	Mild, if present	The dominant symptom — if the patient does not report itching, reconsider allergic conjunctivitis	Mild irritation/burning more than itching
Associated findings	May follow otitis media in children; no preauricular node in most cases	Preauricular lymph node, recent URTI, conjunctival membranes, subconjunctival hemorrhage	Chemosis (conjunctival swelling), lid edema, history of atopy/seasonal pattern	Lash crusting, missing/misdirected lashes, recurrent styes, meibomian gland dysfunction
Typical course	Self-limited over 1-2 weeks even without treatment; antibiotics modestly shorten this	Self-limited over 1-3 weeks; highly contagious for the first 3-7 days	Persists as long as allergen exposure continues; recurs seasonally	Chronic, relapsing; managed rather than cured
1st-line management	Often no treatment needed; a topical antibiotic modestly shortens recovery	Supportive care only — cold compresses, lubricants	Remove/avoid the allergen; topical antihistamine/mast-cell stabilizer	Lid hygiene: warm compresses plus lid margin cleansing

Distinguishing bacterial from adenoviral (viral) conjunctivitis by clinical exam alone is genuinely difficult — a point-of-care adenovirus antigen test is available in some settings and can help when the distinction changes management.

History

Itching versus pain/photophobia — itching should dominate the history in true allergic conjunctivitis.
Seasonal pattern, known triggers, or contact lens wear.
Personal or family history of atopy — asthma, eczema, allergic rhinitis.
Any thick, ropy discharge or photophobia, which raises concern for vernal/atopic keratoconjunctivitis rather than typical seasonal disease.

Examination

Best corrected visual acuity.
Inspect for chemosis, lid edema, and papillary reaction; evert the upper lid to look for giant papillae if vernal keratoconjunctivitis is suspected.
Fluorescein staining if corneal involvement (shield ulcer) is possible.
Bilateral findings support allergic conjunctivitis — unilateral redness should prompt reconsideration of the diagnosis.

Treatment Targets

Control itching and inflammation.
Identify and reduce allergen exposure.
Prevent corneal complications in severe (vernal/atopic) disease.
Provide symptomatic relief.

Choose Initial Treatment

Direct treatment rule

1st line, typical seasonal/perennial disease allergen avoidance plus a topical antihistamine/mast-cell stabilizer (e.g., olopatadine or ketotifen) — most patients respond well to this combination.

Vernal or atopic keratoconjunctivitis needs specialist-directed therapy — this may include a short, supervised course of a topical corticosteroid for flares, or a topical immunomodulator (cyclosporine, lifitegrast) for chronic control, given the real corneal risk of undertreated disease.

Do not use an ophthalmic corticosteroid outside specialist supervision — real efficacy for allergic flares, but long-term use raises glaucoma/cataract risk and needs monitoring.

Non-Pharmacologic Treatment

Identify and avoid/reduce the specific allergen where possible — pollen, dust mite, pet dander, a specific cosmetic or contact lens solution.
Cold compresses for symptomatic relief.
Stop wearing contact lenses during a flare; consider a different lens type or care solution if giant papillary conjunctivitis related to lens wear is suspected.
Avoid eye rubbing — worsens mast-cell degranulation and can contribute to mechanical corneal irritation.
Preservative-free artificial tears can help dilute and flush allergen from the ocular surface.

Pharmacologic Treatment Options

Drug / intervention	Role	Dose / use	Important adverse effects	Teaching points
Olopatadine ophthalmic Preferred	Typical allergic conjunctivitis	0.1%: 1-2 drops Q6-8H; 0.2%: 1 drop daily	Minor stinging on instillation	Mast-cell-stabilizing antihistamine; once-daily formulation available.
Ketotifen ophthalmic Alternative	Typical allergic conjunctivitis	1 drop Q8-12H	Minor stinging on instillation	Mast-cell-stabilizing properties; also available as a medicated contact lens.
Bepotastine besilate Alternative	Typical allergic conjunctivitis	1 drop BID	Minor stinging; mild/transient taste disturbance	Mast-cell-stabilizing properties.
Ketorolac tromethamine ophthalmic Alternative	Itching relief, adjunct	1 drop QID (0.4-0.5%) or BID (0.45%)	Mild-moderate stinging; epitheliopathy with prolonged frequent use	An NSAID option specifically labelled for seasonal allergic conjunctivitis itching in some formulations.
Cyclosporine ophthalmic Special situation	Vernal/atopic keratoconjunctivitis, specialist-directed	1 drop BID	Ocular burning/pain on instillation	Response may take up to 3 months. Prescribe on the advice of an eye-care professional.
Lifitegrast Special situation	Vernal/atopic keratoconjunctivitis, specialist-directed	1 drop BID	Eye irritation/pain, transient blurred vision, dysgeusia	Some initial relief after 2 weeks; full response may take months.

Special Populations

Pregnancy/breastfeeding

Topical ophthalmic antihistamines/mast-cell stabilizers have minimal systemic absorption. Discuss any topical corticosteroid or immunomodulator use with the prescriber managing the pregnancy.

Children

Vernal keratoconjunctivitis predominantly affects children and young adults and needs ophthalmology co-management given the corneal risk — do not manage as simple seasonal allergic conjunctivitis.

Contact lens wearers

Giant papillary conjunctivitis related to lens wear or lens-care solution needs the trigger identified and modified (different lens material, care system, or wear schedule), not just symptomatic antihistamine treatment alone.

Monitoring & Follow-Up

Reassess if symptoms do not improve within 1-2 weeks of allergen avoidance plus topical therapy. Seasonal disease should improve as allergen exposure declines; perennial or unusually severe/persistent disease warrants reconsidering vernal or atopic keratoconjunctivitis and referring for specialist assessment.

Treatment Failure / Next Step

Reconfirm the diagnosis and specifically re-examine for giant papillae or corneal involvement suggesting vernal/atopic keratoconjunctivitis rather than assuming simple treatment failure.
Reassess for an unidentified or ongoing allergen exposure, including contact lens solutions and cosmetics.
Escalate to a specialist-directed topical corticosteroid or immunomodulator (cyclosporine, lifitegrast) for confirmed severe/chronic disease.
Refer to ophthalmology for any corneal involvement, or disease not responding to standard topical antihistamine/mast-cell-stabilizer therapy.

Common Errors to Avoid

Prescribing a topical antibiotic for allergic conjunctivitis — does not treat an allergic reaction and delays correct management.
Missing vernal or atopic keratoconjunctivitis by treating a child or atopic adult with severe, chronic disease the same as typical seasonal allergic conjunctivitis.
Using an ophthalmic corticosteroid for routine allergic conjunctivitis without specialist supervision — real efficacy, but long-term risk of glaucoma/cataracts requires monitoring.
Overusing ophthalmic vasoconstrictors/decongestants for allergic redness — causes rebound hyperemia and tachyphylaxis; limit to occasional, short-term use.^[4]
Not asking specifically about itching — the single most useful symptom for distinguishing allergic from bacterial/viral conjunctivitis.

Clinical Decision Algorithm

Algorithm A — Red-eye triage (apply first, regardless of suspected cause)

Patient presents with a red eye

Assess for warning signs: limbal injection, corneal opacity, pain/photophobia unrelieved by anesthetic, reduced vision, pupil abnormality, trauma, contact-lens-related ulcer, or suspected chlamydial/gonococcal/herpetic/COVID-19 conjunctivitis

Any warning sign present

Refer immediately to ophthalmology (or optometry if unavailable) — do not manage as simple conjunctivitis or blepharitis

No warning signs

Proceed to condition-specific assessment and management

Algorithm B — Allergic conjunctivitis management

No red flags; itching dominant, bilateral, atopy/seasonal history

Giant papillae, thick ropy discharge, photophobia, or corneal involvement

Suspect vernal/atopic keratoconjunctivitis — refer to ophthalmology for specialist-directed therapy

Typical seasonal/perennial itching and chemosis, no red flags

Allergen avoidance + topical antihistamine/mast-cell stabilizer

No improvement after 1-2 weeks: reassess allergen exposure and reconsider severe disease

Drug Tables

How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.

Ophthalmic antihistamines and mast-cell stabilizers

1st line for typical seasonal/perennial allergic conjunctivitis.

Drug	Dosage	Adverse effects	Comments
Olopatadine	0.1%: 1-2 drops Q6-8H 0.2%: 1 drop daily 0.7%: 1 drop daily	Minor stinging on instillation	Mast-cell-stabilizing properties.
Ketotifen	All ages: 1 drop Q8-12H	Minor stinging on instillation	Also available as a medication-releasing daily disposable contact lens.
Bepotastine besilate	All ages: 1 drop BID	Minor stinging; mild/transient taste disturbance	Mast-cell-stabilizing properties.
Sodium cromoglycate	All ages: 1-2 drops 4-6 times/day	Minor stinging on instillation	Does not provide immediate relief — may take 2-3 days to see improvement.
Lodoxamide	All ages: 1-2 drops QID	Minor stinging on instillation	Does not provide immediate relief — may take 2-3 days to see improvement. Specifically indicated for vernal keratoconjunctivitis.

Ophthalmic NSAIDs

Ketorolac has specific labelling for seasonal allergic conjunctivitis itching in some formulations.

Drug	Dosage	Adverse effects	Comments
Ketorolac tromethamine	All ages: 1 drop QID (0.4-0.5%) or BID (0.45%)	Mild-moderate stinging; epitheliopathy/ulceration with prolonged frequent use

Ophthalmic corticosteroids

For flares of vernal/atopic keratoconjunctivitis, specialist-directed only, short-term (typically ≤2 weeks) with monitoring — long-term use raises glaucoma/cataract risk.

Drug	Dosage	Adverse effects	Comments
Loteprednol	All ages: 1 drop TID-QID for up to 14 days	Minor stinging; glaucoma/cataracts with long-term use	May be less likely to raise intraocular pressure than other topical corticosteroids — often preferred for allergic flares.
Fluorometholone	All ages: 1-2 drops BID-QID	Minor stinging; glaucoma/cataracts with long-term use	May be less likely to raise intraocular pressure than other corticosteroids.

Ophthalmic immunomodulators

For chronic control of vernal/atopic keratoconjunctivitis — specialist-directed; full response may take weeks to months.

Drug	Dosage	Adverse effects	Comments
Cyclosporine ophthalmic	All ages: 1 drop BID	Ocular burning/pain on instillation	Allow 15 minutes before/after ocular lubricants. Response may take up to 3 months.
Lifitegrast	All ages: 1 drop BID	Eye irritation/pain, transient blurred vision, dysgeusia	Some patients notice initial relief after 2 weeks; full response may take months.

References

Conjunctivitis: a systematic review of diagnosis and treatment — JAMA (Azari AA, Barney NP). JAMA 2013;310(16):1721-1729
Bedside diagnosis of the 'red eye': a systematic review — American Journal of Medicine (Narayana S, McGee S). Am J Med 2015;128(11):1220-1224
Vernal keratoconjunctivitis: a review — Clinical and Experimental Ophthalmology (Leonardi A). Clin Exp Ophthalmol 2013;41(5):481-491
Low-dose brimonidine for relief of ocular redness: integrated analysis of four clinical trials — Clinical and Experimental Optometry (Ackerman SL, Torkildsen GL, McLaurin E, et al.). Clin Exp Optom 2019;102(2):131-139
Conjunctivitis Preferred Practice Pattern — American Academy of Ophthalmology (Hoskins Center for Quality Eye Care, PPP Cornea/External Disease Committee). 2023 update, published 2024

Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.